Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2805-2810

  Ishida, Yoshinori ^a   Kawakemi, Kazuyuki ^a   Tanaka, Yoko ^a   Kanehira, Eiji ^a   Omura, Kenji ^a   Watanabe, Go ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Gastric cancer; Pharmacogenomics; TS polymorphism

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; MESSENGER RNA; THYMIDYLATE SYNTHASE;

AMINO ACID SEQUENCE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG TARGETING; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA TRANSLATION; STOMACH CANCER; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL RATE; THYMIDYLATE SYNTHASE;

EID: 0036765664     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Noguchi Y, Imada T, Matumoto A, Coit DG and Brennan MF: Radical surgery for gastric cancer: a review of the Japanese experience. Cancer 64: 2053-2062, 1989.
2. Danenberg PV: Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473: 73-92, 1977.
3. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M, Higuchi A, Satoh A, Mizumoto T and Hamamoto R: Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res 19: 5621-5626, 1999.
4. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, TsaoWei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
5. Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC and Cheng AL: High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5 -fluorouracil based systemic chemotherapy. Cancer 82: 1626-1631, 1998.
6. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T and Altman S: Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res 15: 1259-1270, 1987.
7. Horie N, Aiba H, Oguro K, Hojo H and Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′ erminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20: 191-197, 1995.
8. Kawakami K, Omura K, Kanehira E and Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19: 3249-3252, 1999.
9. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, Omura K, Watanabe G and Danenberg PV: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7: 4096-4101, 2001.
10. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Monge RM, Salgado E, Angeletti S and Brugarolas A: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19: 1779-1786, 2001.
11. Ieopetta B, Grieu F, Joseph D and Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85: 827-830, 2001.
12. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong Y-P, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S and Lenz H-J: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. The Pharmacogenomics Journal 1: 65-70, 2001.
13. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV and Laird PW: CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 59: 2302-2306, 1999.
14. Omura K, Kawakami K, Kanehira E, Nagasato A, Kawashima S, Tawaraya K, Watanabe S, Hirano K, Shirasaka T and Watanabe Y: The number of 5-fluoro-2′-deoxyuridine-5′-monophosphate binding sites and reduced folate pool in human colorectal carcinoma tissues: changes after tegafur and uracil treatment. Cancer Res 55: 3897-3901, 1995.
15. Leichman L, Lenz HJ and Leichman CG: Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5- fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 31: 1306-1310, 1995.
16. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
17. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.
18. Yu CC-W, Levison DA, Dunn JA, Ward LC, Demonakou M, Allurn WH and Hallisey MT: Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. Br J Cancer 71: 1106-1110, 1995.
19. Stetala LP, Kosma V-M, Marin S, Lipponen PK, Eskelinen MJ, Syrjanen KJ and Alhava EM: Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer 74: 766-772, 1996.
20. Stelzner S and Emmrich P: The mixed type in Lauren's classification of gastric carcinoma: histologic description and biologic behavior. Gen Diagn Pathol 143: 39-48, 1997.